LFA-REAL is a two part system, based on a series of simple questions and observations, to determine a treatment’s impact on the patient’s health and daily life.
C4d as Markers of Lupus Nephritis
Diagnosing and monitoring lupus-related kidney disease, called lupus nephritis, often requires an invasive kidney biopsy. Dr. Amy Kao of the Allegheny-Singer Research Institute in Pittsburgh, has conducted a study, supported by the Lupus Foundation of America, on evaluation of CD4 molecules on T-cells as a possible marker for lupus nephritis. Validating such a biomarker for this potentially life-threatening complication of lupus would eliminate or greatly reduce the need for kidney biopsies. In this video, Dr. Kao discusses her study and future steps for this line of investigation.
More than 250 lupus activists from 31 states joined the fight for more lupus research funding.